

11-1-2021

Diabetes in Kidney Transplantation.

Maria P Martinez Cantarin
Thomas Jefferson University

Follow this and additional works at: <https://jdc.jefferson.edu/medfp>

[Let us know how access to this document benefits you](#)

Recommended Citation

Martinez Cantarin, Maria P, "Diabetes in Kidney Transplantation." (2021). *Department of Medicine Faculty Papers*. Paper 353.
<https://jdc.jefferson.edu/medfp/353>

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's [Center for Teaching and Learning \(CTL\)](#). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Medicine Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Diabetes in kidney transplantation

Maria P Martinez Cantarin, MD

833 Chestnut Street Suite 700, Philadelphia, PA, 19147. Phone 215-955-6550, Fax 215-503-4099

maria.p.martinezcantarin@jefferson.edu

Sidney Kimmel Medical College at Thomas Jefferson University

Department of Medicine, Division of Nephrology

The author reports no conflict of interest.

Short title: Diabetes and transplant

1. **Abstract**

Diabetes mellitus (DM) is one of the most common complications after kidney transplantation and is associated with unfavorable outcomes including death. DM can be present before transplant but post-transplant diabetes mellitus (PTDM) refers to diabetes that is diagnosed following solid organ transplantation. Despite its high prevalence, optimal treatment to prevent complications of PTDM are unknown. Medical therapy of pre-existent DM or PTDM after transplant is challenging due to frequent interactions between antidiabetic and immunosuppressive agents. There is also frequent need for medication dose adjustments due to residual kidney disease and a higher risk of medication side effects in patients treated with immunosuppressive agents. Sodium glucose 2 inhibitors (SGLT2-i) have demonstrated a favorable cardio-renal profile in patients with DM without a transplant and hence hold great promise in this patient population although there is concern about the higher risk of urinary tract infections. The significant gaps in our understanding of the pathophysiology, diagnosis and management of diabetes mellitus after kidney transplantation need to be urgently addressed.

2. **Clinical summary**

- a. Diabetes mellitus after transplant, which includes pre-existing diabetes and post-transplant diabetes, is extremely common and is associated with increased morbidity and mortality.
- b. The pathogenesis of post-transplant diabetes shares similarities with other subgroups of type 2 diabetes. However, PTDM presents distinct drivers for metabolic dysfunction including calcineurin inhibitor toxicity to the pancreatic beta cell, thus making PTDM a separate entity.

- c. Fasting glucose and hemoglobin A1c may not reflect the altered metabolism after an organ transplant making the diagnosis of PTDM more challenging. Oral glucose tolerance test should be considered the gold standard for its diagnosis.
- d. Optimal treatments goals in PTDM are unknown.
- e. SGLT2-i have demonstrated efficacy and safety in the treatment of non-transplant related DM with improvement in cardiovascular risk and decrease in kidney disease progression. However, SGLT2-i therapy post-kidney transplant may pose a substantially higher risk of genitourinary infections and vasomotor acute kidney injury. Studies to determine whether SGLT2-i provide clinical benefits including cardiovascular prevention and nephroprotective effects are need post-transplant.

3. Introduction

DM is a common complication of kidney transplantation. In the US, almost 50% of the incident end stage kidney disease patients have DM and diabetes is the primary cause of kidney disease in 22% of kidney transplant recipients¹. Furthermore, 2 to 50% of patients that did not have DM before kidney transplant, will develop it post-transplant². DM in a kidney transplant recipient is associated with significant morbidity and mortality independently of whether it was present pre-transplant. Diabetic kidney transplant recipients have reduced overall survival³ with increased cardiovascular complications and infections.

Despite its high prevalence and association with poor outcomes, optimal management strategies for DM after kidney transplant are unknown. Interactions between immunosuppressive medications and anti-diabetic agents make its treatment challenging. The persistence of chronic kidney disease (CKD), high frequency of episodes of acute kidney injury (AKI) and worsening kidney function also complicates therapy.

The current review will focus on the burden of type 2 diabetes (T2DM) after transplant with a brief discussion on the treatment of type 1 diabetes (T1DM). We will review the epidemiology and pathogenesis of PTDM, the diagnostic challenges, risk factors and outcomes as well as management strategies.

4. Post-transplant diabetes mellitus

a. Definition

PTDM refers to diabetes mellitus that is diagnosed after kidney transplant, and acknowledges that some patients may have had undiagnosed pre-transplant DM. This is in contrast to the old nomenclature of new onset diabetes after transplant (NODAT) that assumed that the patients did not have DM prior to transplant. Currently, it is estimated that up to 10% of patients with the diagnosis of PTDM have undiagnosed diabetes pre-kidney transplantation⁴.

b. Incidence.

The scientific literature reports wide variations in the prevalence of DM after transplant, which is partly due to a lack of historic consistent criteria for its diagnosis. In 2003 consensus guidelines were published to aid in the diagnosis of diabetes mellitus after transplant⁵ and more contemporary series using the guideline's criteria reflect a PTDM prevalence of 10-30%^{6,7}. The incidence of PTDM is higher in non-kidney organ transplant recipients. Incidence of PTDM in heart transplant recipients ranges between 20-30%, in liver transplant recipients 20-40% and lung transplant recipients 20-40%⁸.

c. Diagnosis

The diagnosis of PTDM relies on the same criteria that are used to diagnose DM in the non-transplant population⁹. In brief, diabetes mellitus after kidney transplant is diagnosed if fasting glucose ≥ 126 mg/dL (7 mmol/L) on more than one occasion, random glucose ≥ 200 mg/dL (11.1 mmol/L) with symptoms, or a 2-hour glucose level after a 75-g oral glucose tolerance test (OGTT) ≥ 200 mg/dL (11.1 mmol/L). OGTT is

more sensitive than fasting glucose alone and should be considered the gold standard for the early diagnosis of PTDM since PTDM presents often with postprandial hyperglycemia and normal fasting glucose levels^{10,11}. In 2013 a panel of transplant nephrologists, surgeons, diabetologists, and clinical scientists reviewed and updated the criteria for PTDM. The review clarified issues specific to transplant recipients¹² such as the use of hemoglobin A1c (HbA1c) and proposed standard PTDM nomenclature. Some key points from the consensus conference will be highlighted here.

Short term hyperglycemia is common in the immediate post-transplant period and is attributable in part to different post-surgical stressors such as inflammation, use of high dose steroids for the induction of immunosuppression, infections and a high frequency of enteral or parenteral nutrition^{13,14}. As a result, in order to ensure a uniform and consistent diagnosis of PTDM, it was proposed that the diagnosis should be made when allograft function and immunosuppression levels are stable, and other perioperative complications (e.g. infection and/or rejection) are resolved.

OGTT should remain the gold standard for the diagnosis of PTDM as it is more sensitive than relying exclusively on fasting glucose levels^{10,11}. OGTT also screens for impaired glucose tolerance (IGT) which is not only a risk factor for development of PTDM but is also an independent risk factor for cardiovascular disease and mortality^{15,16}. Despite its value, OGTT is not used widely in clinical practice due to need for more resources.

HbA1c levels in the early post-transplant period are unreliable, especially if low. After transplant, erythropoiesis is reduced with immunosuppressive medications and the persistence of kidney disease driving anemia. Treatment of anemia often requires erythropoietin analogs which will alter red blood cell survival. Post-transplant transfusions may also influence HbA1C levels. Due to changes in red cell turnover, hemoglobin concentration, and even glucose concentration in the early post-transplant period, a normal HbA1c does not exclude PTDM¹⁷. On the other hand, glycosylated hemoglobin levels between 5.7 and

6.4% in the early post-transplant period or with anemia, may reflect the need to perform an OGTT since it is the best diagnostic tool and should alert us to the possibility of PTDM.

After the 2013 consensus meeting, most subsequent transplant guidelines advocate screening for PTDM with fasting blood sampling and HbA1c to determine the patients at risk who will benefit from an OGTT.

d. Risk factors

Risk factors for the development of PTDM are similar to those that increase the risk prior to transplantation, however, transplant specific risks also contribute (**Table 1**). The use of immunosuppressive medications including calcineurin inhibitors (CNIs), steroids and mammalian target of rapamycin (mTOR) inhibitors, infections such as hepatitis C, and hypomagnesemia are specific factors associated with increased risk of PTDM. CNIs, which include tacrolimus (Tac) and cyclosporine (CSA), are the cornerstone of immunosuppressive therapy, and are more commonly used than mTOR inhibitors such as sirolimus or everolimus. CNIs promote PTDM by inhibiting crucial signaling pathways for pancreatic β -cell growth and function¹⁸. The diabetogenic potential of CNIs is dose dependent¹⁹ and Tac is considered more diabetogenic than CSA²⁰. mTOR inhibitors are also associated with development of PTDM at higher rates than CSA but at lower rates than Tac²¹. Weight gain, which induces insulin resistance, is another factor that is more prevalent in post-transplant patients. Significant weight gain after kidney transplantation is common, as a consequence of the use of steroids and the dissipation of uremic anorexia. Counseling on appropriate weight management and healthy habits should be part of the post-transplant counseling and avoidance of weight gain may reduce risk of PTDM.

e. Pathogenesis

PTDM shares multiple pathophysiological characteristics with pre-transplant DM but, since PTDM has distinct mechanisms that eventually lead to hyperglycemia, is now considered a separate entity. As in pre-transplant DM, PTDM presents dysfunctional insulin sensitivity (IS)^{22,23}, abnormal insulin production with

pancreatic β -cell dysfunction^{24,25}, lack of glucagon suppression with hyperglycemia²⁶, as well as hypertriglyceridemia, obesity, and low-grade inflammation^{27,28}. The dominant mechanism that leads to the development of PTDM is still an area of debate although several groups propose that β -cell dysfunction is the main pathophysiological process^{10,11,24,25}. The role of insulin resistance in the development of PTDM is less clear as timing and methods used for evaluation of insulin sensitivity vary widely between studies²⁹. One way to explain the post-transplant differences observed could be the fact that insulin sensitivity is a dynamic process that changes significantly over time. This possibility was examined by Hjelmessaeth et al.^{30,31} who studied insulin sensitivity by OGTT and insulin measurements at 10 weeks, 1 year, and 6 years post renal transplantation. Early post-transplant patients had decreased insulin sensitivity and defects in insulin secretion. The magnitude of the defect on insulin sensitivity and secretion correlated with the glucose tolerance state and development of PTDM. Between 1- and 6-years post-transplant, patients with PTDM continue to have significant reduction of insulin secretion but no longer show significant differences in insulin sensitivity compared to patients with normal glucose tolerance. Data from these studies may reflect the fact that defects in insulin secretion after transplant are more constant, most likely due to the persistent use of β -cell toxic immunosuppression whereas insulin sensitivity can vary more widely. More recently, alterations in the incretin axis between the gut and pancreas have also been demonstrated in patients with PTDM. Patients with DM have a defect in the incretin system with decreased insulin and increased glucagon release in response to a glucose load that improves with glucagon-like peptide 1 (GLP1) agonist treatment. Patients with PTDM, like those with DM unrelated to transplantation, have reduced glucose-induced insulin secretion and attenuated glucagon suppression when studied with the hyperglycemic clamp, the gold standard test to assess insulin secretion capacity and beta cell response to glucose. In this study, GLP1 infusion also improved insulin and glucagon responses to hyperglycemia in patients with PTDM²⁶.

f. Outcomes/Complications

DM pre- or post-transplant is associated with increased morbidity and mortality. Similarly to T2DM, development of PTDM is associated with a significant increase in cardiovascular disease³²⁻³⁴ risk and death^{7,14,35}. Specifically, PTDM is associated with a 60% increase in post-transplantation myocardial infarction³⁶, increased risk of cerebrovascular accidents³³, as well as aortic or lower extremity arterial disease^{33,34}. Interestingly, despite the higher mortality risk, graft viability is not impacted by PTDM since death censored graft loss does not differ¹⁶. Besides the increased risk of macrovascular disease and death with development of PTDM, these patients may also develop microvascular disease related complications at an accelerated rate³⁷. The risk of increased morbidity and mortality with PTDM has also been demonstrated in pre-diabetic states including impaired glucose tolerance and impaired fasting glucose^{15,38}. To summarize, PTDM and its precursor states are associated with poor outcomes including a higher risk of microvascular and macrovascular disease although graft survival is not affected.

5. Management of diabetes mellitus after transplant

Management strategies for treatment of PTDM should aim to improve β - cell function and decrease insulin resistance.

In contrast with T2DM, there are no specific glucose or A1c targets for the treatment of PTDM as there is no data on the degree of glycemic control that is associated with reduction of complications after development of PTDM³⁹. Despite this, most transplant centers will aim for HbA1c of 7-7.5% as suggested in the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines for the management of transplant recipients⁴⁰. Due to the possibility that diabetic complications occur early after transplant³⁷ and lead to poor outcomes, we advocate treating PTDM aggressively and promptly after diagnosis making every effort to avoid hypoglycemia. On the other hand, it is reasonable to consider higher thresholds for older and debilitated patients.

a. Lifestyle changes and bariatric surgery.

Lifestyle modifications should be emphasized as one of the initial treatments of PTDM since a combination of exercise and weight loss improves insulin sensitivity and β -cell function in diabetic patients^{41,42} although its effectiveness in PTDM is limited to a few small studies. A combined approach to diet and weight loss have shown complete reversal of impaired glucose tolerance after 6 months post-transplant in a non-randomized study⁴³ whereas a randomized control trial of active versus passive lifestyle interventions was only able to show improvement in weight loss and reduction of fat mass without improvement in glucose metabolism⁴⁴. Unfortunately, more data are needed to determine the real effect of lifestyle modifications to prevent development of PTDM. The role of bariatric surgery before or after kidney transplantation to decrease the risk of PTDM is also underexplored, with just a few reports citing the experience of individual centers in a small number of patients⁴⁵⁻⁴⁷. Due to the evolution and improvement of bariatric surgery techniques, excellent outcomes and safety profile in the general non – transplant population and growing data from the transplant population⁴⁸, bariatric surgery could be considered for a select population depending on the risk factor profile and expected time to transplantation.

b. Antidiabetic medications

A recent review by Cohen et al.⁴⁹ summarizes therapeutic studies in the context of PTDM and highlights the paucity of available data. Older drugs such as the biguanide metformin, secretagogues such as glipizide and repaglinide as well as thiazolidinediones have been used for the treatment of PTDM and have demonstrated safety, low drug to drug interactions with immunosuppressive medications and efficacy in lowering blood glucose. It is important to remember that CNIs are metabolized via cytochrome p450 3A4 (CYP3A4) so drugs that interact with the CYP3A4 pathway can significantly alter CNIs drug levels. At the time of starting antidiabetic treatment several issues should be considered: a) drug to drug interactions, b) exacerbation of the side effects of immunosuppressant medications when used concomitantly with oral antidiabetic therapies with similar side effects, and c) kidney clearance of the different drugs as transplant patients will have different degrees of residual kidney disease.

i. Post-surgical period

Insulin is the main antidiabetic medication used in the immediate post-transplant period. Data from a small proof of concept study showed that patients with blood glucose >140 mg/dL treated with insulin early post-transplantation had decreased risk of PTDM compared to patients treated with oral antidiabetic agents. The study proposed early insulin therapy to protect β -cell function toxicity from hyperglycemia and decrease PTDM incidence¹⁴. A large randomized control trial, the ITP-NODAT trial (Early postoperative basal insulin therapy for the prevention of post-transplant diabetes onset after kidney transplantation), also corroborates the findings of the small non randomized study⁵⁰.

Dipeptidyl peptidase 4 (DPP-4) inhibitors have been shown to improve insulin sensitivity as well as β -cell function⁵¹. Vidagliptin, a DPP-4 inhibitor, has been shown to be safe and efficacious in kidney transplant patients⁵² and a randomized trial is underway to test if vidagliptin could prevent PTDM development when used immediately post-transplant compared to placebo⁵³.

ii. Metformin

Metformin is still considered the first line therapy for DM treatment, but the association of metformin with lactic acidosis specifically in the setting of worsening kidney function complicates its use in post-transplant patients. Despite the risk of lactic acidosis, metformin can still be prescribed to patients with moderately reduced kidney function (glomerular filtration rate or GFR 30-59 mL/min)⁵⁴. Metformin has minimal drug-drug interactions with immunosuppressant medications, but potentiation of metformin gastrointestinal (GI) side effects is possible when used concomitantly with mycophenolate mofetil (MMF). Close monitoring of kidney function is advisable during metformin therapy, in order to avoid potential treatment-related complications. In a small randomized trial that used metformin in patients that developed IGT 4-12 weeks post-transplant, metformin was well tolerated but did not show differences in metabolic profile compared to untreated patients⁵⁵. Recent guidelines by the Association of British Clinical

Diabetologists (ABCD) and by the British Renal Association (RA) on the Detection and Management of Diabetes post-Solid Organ Transplantation continue to recommend metformin use if GFR allows it as one of the first line therapies in PTDM⁵⁶. Further studies are needed to determine the efficacy of metformin in the prevention and management of PTDM.

iii. Sulfonylureas and glinides

Sulfonylureas and glinides stimulate pancreatic secretion of insulin independently of glucose levels. In contrast to glinides, most of the sulfonylureas significantly accumulate with kidney disease increasing the risk of hypoglycemia. Glinides are safer drugs in patients with kidney disease and more widely used post-transplantation. Unfortunately, despite frequent clinical utilization, there are only a few small studies that have tested these drugs in the setting of PTDM^{57,58}.

iv. Glucagon-like peptide 1 receptor agonists (GLP1-RAs)

GLP1-RAs improve glycemic control in T2DM through enhanced glucose-dependent insulin secretion, inhibition of glucagon release, delayed gastric emptying, appetite suppression, and inhibition of β -cell apoptosis⁵⁹. Liraglutide, semaglutide and dulaglutide do not have significant kidney clearance, making them attractive agents in kidney transplant recipients. There is minimal data on liraglutide and dulaglutide safety after kidney transplantation⁶⁰⁻⁶². In theory, GLP1-RAs may potentially exacerbate the frequent GI side effects seen with MMF due to their effect in delaying gastric emptying although this has not been observed in studies using dulaglutide.

v. Dipeptidyl peptidase 4 (DPP-4) inhibitors

DPP-4 inhibitors inactivate DPP4, the enzyme responsible for inactivation of glucose-dependent insulinotropic polypeptide (GIP) and GLP-1, thus enhancing glucose control. In contrast to GLP1-RAs, DPP-4 inhibitors have significant kidney clearance and dose reduction is necessary in patients with CKD.

Linagliptin is the only DPP-4 inhibitor that is non-renally cleared with predominant biliary clearance. DPP-4 inhibitors have some interactions with CNI metabolism as sitagliptin increases CSA levels and vidagliptin can decrease Tac trough levels. Linagliptin, sitagliptin and vidagliptin have been used in kidney transplant recipients with some benefits^{52,63,64} and currently vidagliptin is being studied in a randomized controlled study for its use in the early post-operative period⁵³.

vi. Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2-i)

The two newest additions to the DM therapy armamentarium have been SGLT2-i and GLP1-RAs. SGLT2-i have received more attention recently as their use in diabetic patients is associated with lower cardiovascular disease risk and progression of CKD⁶⁵⁻⁶⁹. SGLT2-i selectively inhibit the sodium glucose co-transporter in the proximal convoluted tubule preventing glucose reabsorption. This mechanism of action results in a loss of significant amounts of glucose in the urine. Increased glycosuria facilitates urinary water losses which results in decreased blood pressure and weight loss, but also increases the risk of urinary tract infections and ketoacidosis.

SGLT2-i have shown evidence of reducing kidney disease progression in patients with T2DM⁷⁰⁻⁷² but trials in the PTDM population have been scarce. These benefits are independent of glucose control as the mean changes of HgA1c reported in clinical trials has been modest (around 0.5-0.6%)^{66,67}. Recent published reviews of trials involving use of SGLT2-i in transplant recipients advocate for their widespread use^{73,74} despite paucity of data. Currently, only a few observational and retrospective studies with SGLT2-i in a small number of transplant recipients⁷⁵⁻⁷⁸ have been published and their main characteristics have been summarized in Table 2. Similarly to the diabetic trials in the non-transplant population, the efficacy of SGLT2-i in diabetic control is quite modest when used in patients with PTDM so most guidelines propose its use as an add on therapy^{75-77,80,82}

Despite positive reviews, the main barrier to its widespread use in the transplant population has been the increased risk of bacterial and fungal infections of the genitourinary tract and perineum, including Fournier's gangrene, increased risk of amputations, and euglycemic acidosis. The increased risk of infections is thought to be related to the increased glucose content in the urine that makes a more favorable environment for bacterial growth. Transplant patients are inherently at higher risk for urinary tract and perineal infections due to immunosuppression and the physiological/anatomical changes that occur in the post-transplant genitourinary tract. Current trials that used SGLT2-i in transplant recipients have not demonstrated a higher risk of infection but data are limited due to small patient numbers. Other risks associated with SGLT2-i use include hemodynamic AKI due to afferent arteriole vasoconstriction coupled with volume loss due to its diuretic effect. None of these side effects have been reported in the trials that involved kidney transplant recipients, but most of the trials that used SGLT2-i post-transplant excluded patients with recurrent UTIs and patients within the first post-transplant year to minimize toxicity risk.

In summary, despite its modest anti-glycemic effects, SGLT2-i may confer similar cardiovascular and renal protection in kidney transplant recipients although further randomized control trials are needed to confirm this. SGLT2-i should be combined with other anti-diabetic agents but due to its potential for significant side effects, it seems prudent to limit its use to patients without a history of recurrent UTIs or perineal infections and avoid its use during the first post-transplant year. Caution should be used when given concomitantly with diuretics and antihypertensive medications due to potential changes in volume status. Consider holding SGLT2-i during acute illness to minimize the risk of diabetic ketoacidosis and vasomotor AKI.

c. Modification of immunosuppression

Immunosuppression is one of the most important modifiable risk factors for PTDM. Tailoring immunosuppression to patient risk for PTDM development is a logical step. Despite this, changes in immunosuppression agents during the first post-transplant year carries the risk of promoting rejection. It is well known that calcineurin inhibitors decrease insulin release from pancreatic β - cells and the use of Tac is associated with higher risk of PTDM compared to CSA²⁰. Conversion from Tac based to CSA based immunosuppression in patients with PTDM was able to reverse diabetes mellitus in a significant number of patients⁸³. Also, since the risk of PTDM is dose dependent, other studies have demonstrated a benefit on β -cell function with increased insulin secretion capacity once average Tac trough levels were decreased from 9.5 to 6.4 ng/mL⁸⁴. The use of mTOR inhibitors is also associated with the development of PTDM²¹ probably with lower risk than Tac but higher than CSA⁸⁵. Some of the new immunosuppressant agents such as Belatacept have demonstrated metabolic benefits with higher insulin release and lower risk of PTDM development compared to Tac use⁸⁶ and this may be an interesting option that should be rigorously explored in clinical trials in subjects at high risk for PTDM. Antimetabolite use has not been demonstrated to increase PTDM risk. Despite the well-known role of steroids in the development of hyperglycemia and diabetes, the effect of steroids on the incidence of PTDM remains controversial. Several studies have shown that the risk of developing diabetes mellitus post-transplant is similar in patients that are maintained on steroids, versus patients that were not exposed to steroids or only exposed to steroids for a limited period of time⁸⁷⁻⁹⁰. On the other hand, rapid steroid withdrawal in a study from Germany showed significant reduction in the development of PTDM⁹¹. Transplant patients on 5 mg of prednisone demonstrated similar insulin sensitivity to patients not on steroid therapy⁹². Unfortunately, there is no data suggesting a benefit of immunosuppression adjustments without risk for increased rejection to prevent the development of PTDM and caution should be used when changes are made with the sole purpose of preventing diabetes.

d. Insulin pump treatment versus pancreas transplant for T1DM.

Intensive insulin therapy either with intermittent subcutaneous injections or by continuous subcutaneous delivery systems remains the cornerstone of therapy for patients with T1DM. Intensive insulin therapy has been demonstrated to decrease microvascular disease progression in patients with T1DM but, despite this, only a small proportion of patients meet the HgA1c goal set by the American Diabetes Association (ADA) in the T1D Registry^{93,94} and most likely an even-smaller proportion of the general population⁹³. The main barrier to achieve glucose control has been the risk of hypoglycemia. The technological advancements in insulin pumps, continuous glucose monitoring systems (CGMs) and artificial pancreas, where the capabilities of insulin pumps and CGMs are combined, have facilitated lower mortality, increased quality of life and decreased incidence of hypoglycemia^{93,95,96}. Despite these new technologies, there are still multiple barriers to optimal glycemic control mainly related to their high cost and challenges in deployment for populations with disabilities. Pancreas transplantation provides the most durable replacement of β -cells in patients with insulin dependent diabetes. It is the most suitable therapy particularly in patients with advanced CKD as pancreas transplantation could be carried out concomitantly or after kidney transplantation. With a kidney transplant, the risk of long-standing immunosuppressive therapy is already accepted so there is less concern about the negative effects of immunosuppression. Pancreas transplantation not only improves quality of life but also has been demonstrated to decrease microvascular end organ damage⁹⁷. With improvements in long term outcomes and decreased morbidity using current surgical techniques, pancreas transplantation is now available to a subset of insulin dependent⁹⁸ T2DM patients. In this subset, outcomes were excellent, with close to 90% of the patients being free of diabetes 5 years post-transplant. Pancreas transplantation without a kidney is mainly recommended for patients with T1DM with significant hypoglycemic unawareness despite CGMs or who are unable to achieve benefits of advance monitoring technologies. Patients should be free of CKD and proteinuria, as long-term use of immunosuppression will increase the risk of progressive kidney failure due to the nephrotoxicity of CNIs. Islet allotransplantation, where islet cells isolated from a donor are

injected into the portal vein of the recipient, is only available in specialized transplant centers. Less than 2000 islet cell transplants have been performed between 1999 and 2015 in North America. Islet transplantation is minimally invasive but still requires the use of immunosuppression. Recent trials have demonstrated that islet cell transplantation is safe, improves glycemic control, and quality of life⁹⁹. Most of the patients will have resolution of hypoglycemic episodes and will improve glucose control with a secondary goal of achieving insulin independence at least in the short term. Long term insulin independence remains a challenge after islet cell transplantation¹⁰⁰. Future therapies involve the use of embryonic stem cells or pluripotential stem cells, alternative transplant sites, use of other cell types besides β -cells in order to facilitate and prolong engraftment, or even gene editing to decrease cell immunogenicity and eliminate the need for ongoing immunosuppression. In summary, there are both medical and surgical options for T1DM treatment. These therapeutic options should be tailored to the unique circumstances of each patient at the specific moment of their disease course. Appropriateness of surgical and medical options may vary depending on the progression of diabetes during the patient's lifespan.

In summary, management of DM after transplantation remains a significant challenge as diagnosis can be obscured and treatment goals have not been fully delineated. Pharmacological therapies for DM have expanded significantly over the past few years but their role in improving outcomes in PTDM management is unknown. PTDM is an underexplored area within the metabolic disorders that affect kidney disease patients and should be the focus of future research.

Acknowledgements.

The work was primarily funded by the National Institute of Diabetes and Digestive and Kidney Disease (NIDDK) Division of Intramural Research projects RDK111574A (to Dr. Martinez Cantarin)

Table 1: Risk factors associated with the development of post-transplant diabetes mellitus

Factors unrelated to transplantation	Older age ¹⁰¹
	Family history of DM
	Ethnicity Black and Hispanic
	Central obesity ^{102,103}
	Genetic factors ¹⁰⁴
	Sedentary lifestyle
Factors associated with transplantation	Calcineurin inhibitors (tacrolimus >cyclosporine) ²⁰
	Glucocorticoids ⁹²
	Hepatitis C or Cytomegalovirus infection ^{105,106}
	Post-transplant weight gain
	Hypomagnesemia ¹⁰⁷
	Inflammation and relative hypo-adiponectinemia ^{27,28,108}

Table 2. Summary of the studies using SGLT2-i in kidney transplant recipients.

Study reference	Study design	Agent	Population/Follow up	Key Findings
Rajasekeran H et al, 2017 ⁷⁶	Case series, retrospective	Canagliflozin	10 kidney transplant and SPK recipients for 80.5 patient-months	Patients on canagliflozin had small decrease in HgA1c, small decrease in body weight, and a small decrease in GFR.
Mahling et al, 2019 ⁷⁷	Case series, retrospective	Empagliflozin	10 kidney transplant recipients over 12 months	Patients on empagliflozin had stable GFR, and a small decrease in HbA1c.
Shah M et al, 2019 ⁷⁸	Case series, prospective	Canagliflozin	24 kidney transplant recipients over 6 months	Patients on canagliflozin had some weight loss, small reduction in BP and improvement of HgA1c
AlKindi F et al, 2020 ⁷⁵	Case series, retrospective	Empagliflozin and dapagliflozin	8 living kidney transplant recipients over 3-6 months	Patients on SGLT2-i had stable GFR, small decrease in HgA1c, and small decrease in weight.
Halden et al, 2019 ⁷⁹	Randomized, prospective, double blind	Empagliflozin vs placebo	44 kidney transplant recipient over 24 weeks	Empagliflozin use was associated with small changes in HbA1c and weight with no differences in adverse events
Schwaiger, E et al, 2019 ⁸⁰	Prospective study	Empagliflozin	14 diabetic kidney transplant participants	Empagliflozin may be used as add-on therapy for treatment of diabetes after transplant.
Song CC et al, 2021 ⁸¹	Retrospective study	Empagliflozin, canagliflozin and dapagliflozin.	50 kidney transplant participants over 6 months	Patients on SGLT1-i had decrease weight and increase magnesium concentration.

References:

1. Saran R RB, Abbott KC, et al. . US Renal Data System 2019 Annual Data Report: epidemiology of kidney disease in the United States. *Am J Kidney Dis* 2020;75:Svi-Svii.
2. Gomes V, Ferreira F, Guerra J, Bugalho MJ. New-onset diabetes after kidney transplantation: Incidence and associated factors. *World J Diabetes* 2018;9:132-7.
3. Lim WH, Wong G, Pilmore HL, McDonald SP, Chadban SJ. Long-term outcomes of kidney transplantation in people with type 2 diabetes: a population cohort study. *Lancet Diabetes Endocrinol* 2017;5:26-33.
4. Bergrem HA, Valderhaug TG, Hartmann A, et al. Undiagnosed diabetes in kidney transplant candidates: a case-finding strategy. *Clin J Am Soc Nephrol* 2010;5:616-22.
5. Davidson J, Wilkinson A, Dantal J, et al. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. *Transplantation* 2003;75:SS3-24.
6. Shivaswamy V, Boerner B, Larsen J. Post-Transplant Diabetes Mellitus: Causes, Treatment, and Impact on Outcomes. *Endocr Rev* 2016;37:37-61.
7. Eide IA, Halden TA, Hartmann A, et al. Mortality risk in post-transplantation diabetes mellitus based on glucose and HbA1c diagnostic criteria. *Transpl Int* 2016;29:568-78.
8. Jenssen T, Hartmann A. Post-transplant diabetes mellitus in patients with solid organ transplants. *Nat Rev Endocrinol* 2019;15:172-88.
9. Expert Committee on the D, Classification of Diabetes M. Report of the expert committee on the diagnosis and classification of diabetes mellitus. *Diabetes Care* 2003;26 Suppl 1:S5-20.
10. Hecking M, Werzowa J, Haidinger M, et al. Novel views on new-onset diabetes after transplantation: development, prevention and treatment. *Nephrol Dial Transplant* 2013;28:550-66.
11. Hecking M, Kainz A, Werzowa J, et al. Glucose metabolism after renal transplantation. *Diabetes Care* 2013;36:2763-71.
12. Sharif A, Hecking M, de Vries AP, et al. Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions. *Am J Transplant* 2014;14:1992-2000.
13. Chakkera HA, Weil EJ, Castro J, et al. Hyperglycemia during the immediate period after kidney transplantation. *Clin J Am Soc Nephrol* 2009;4:853-9.
14. Hecking M, Haidinger M, Doller D, et al. Early basal insulin therapy decreases new-onset diabetes after renal transplantation. *J Am Soc Nephrol* 2012;23:739-49.
15. Valderhaug TG, Hjelmessaeth J, Hartmann A, et al. The association of early post-transplant glucose levels with long-term mortality. *Diabetologia* 2011;54:1341-9.
16. Valderhaug TG, Hjelmessaeth J, Jenssen T, Roislien J, Leivestad T, Hartmann A. Early posttransplantation hyperglycemia in kidney transplant recipients is associated with overall long-term graft losses. *Transplantation* 2012;94:714-20.
17. Sharif A, Baboolal K. Diagnostic application of the A(1c) assay in renal disease. *J Am Soc Nephrol* 2010;21:383-5.
18. Heit JJ, Apelqvist AA, Gu X, et al. Calcineurin/NFAT signalling regulates pancreatic beta-cell growth and function. *Nature* 2006;443:345-9.
19. Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. *BMJ* 2005;331:810.

20. Vincenti F, Friman S, Scheuermann E, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. *Am J Transplant* 2007;7:1506-14.
21. Johnston O, Rose CL, Webster AC, Gill JS. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. *J Am Soc Nephrol* 2008;19:1411-8.
22. Ekstrand AV, Eriksson JG, Gronhagen-Riska C, Ahonen PJ, Groop LC. Insulin resistance and insulin deficiency in the pathogenesis of posttransplantation diabetes in man. *Transplantation* 1992;53:563-9.
23. Jorgensen MB, Hornum M, van Hall G, et al. The impact of kidney transplantation on insulin sensitivity. *Transpl Int* 2017;30:295-304.
24. Nam JH, Mun JI, Kim SI, et al. beta-Cell dysfunction rather than insulin resistance is the main contributing factor for the development of postrenal transplantation diabetes mellitus. *Transplantation* 2001;71:1417-23.
25. Zelle DM, Corpeleijn E, Deinum J, et al. Pancreatic beta-cell dysfunction and risk of new-onset diabetes after kidney transplantation. *Diabetes Care* 2013;36:1926-32.
26. Halden TA, Egeland EJ, Asberg A, et al. GLP-1 Restores Altered Insulin and Glucagon Secretion in Posttransplantation Diabetes. *Diabetes Care* 2016;39:617-24.
27. Heldal TF, Ueland T, Jenssen T, et al. Inflammatory and related biomarkers are associated with post-transplant diabetes mellitus in kidney recipients: a retrospective study. *Transpl Int* 2018;31:510-9.
28. Cantarin MP, Keith SW, Lin Z, et al. Association of Inflammation prior to Kidney Transplantation with Post-Transplant Diabetes Mellitus. *Cardiorenal Med* 2016;6:289-300.
29. Hornum M, Jorgensen KA, Hansen JM, et al. New-onset diabetes mellitus after kidney transplantation in Denmark. *Clin J Am Soc Nephrol* 2010;5:709-16.
30. Hjelmessaeth J, Hagen M, Hartmann A, Midtvedt K, Egeland T, Jenssen T. The impact of impaired insulin release and insulin resistance on glucose intolerance after renal transplantation. *Clin Transplant* 2002;16:389-96.
31. Hagen M, Hjelmessaeth J, Jenssen T, Morkrid L, Hartmann A. A 6-year prospective study on new onset diabetes mellitus, insulin release and insulin sensitivity in renal transplant recipients. *Nephrol Dial Transplant* 2003;18:2154-9.
32. Hjelmessaeth J, Hartmann A, Leivestad T, et al. The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. *Kidney Int* 2006;69:588-95.
33. Wauters RP, Cosio FG, Suarez Fernandez ML, Kudva Y, Shah P, Torres VE. Cardiovascular consequences of new-onset hyperglycemia after kidney transplantation. *Transplantation* 2012;94:377-82.
34. Cosio FG, Kudva Y, van der Velde M, et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. *Kidney Int* 2005;67:2415-21.
35. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. *Am J Transplant* 2003;3:178-85.
36. Lentine KL, Brennan DC, Schnitzler MA. Incidence and predictors of myocardial infarction after kidney transplantation. *J Am Soc Nephrol* 2005;16:496-506.
37. Burroughs TE, Swindle J, Takemoto S, et al. Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients. *Transplantation* 2007;83:1027-34.
38. Porriani E, Diaz JM, Moreso F, et al. Prediabetes is a risk factor for cardiovascular disease following renal transplantation. *Kidney Int* 2019;96:1374-80.
39. Topitz D, Schwaiger E, Frommlet F, Werzowa J, Hecking M. Cardiovascular events associate with diabetes status rather than with early basal insulin treatment for the prevention of post-transplantation diabetes mellitus. *Nephrol Dial Transplant* 2020;35:544-6.
40. Kidney Disease: Improving Global Outcomes Transplant Work G. KDIGO clinical practice guideline for the care of kidney transplant recipients. *Am J Transplant* 2009;9 Suppl 3:S1-155.

41. Dela F, von Linstow ME, Mikines KJ, Galbo H. Physical training may enhance beta-cell function in type 2 diabetes. *Am J Physiol Endocrinol Metab* 2004;287:E1024-31.
42. Solomon TP, Haus JM, Kelly KR, Rocco M, Kashyap SR, Kirwan JP. Improved pancreatic beta-cell function in type 2 diabetic patients after lifestyle-induced weight loss is related to glucose-dependent insulinotropic polypeptide. *Diabetes Care* 2010;33:1561-6.
43. Sharif A, Moore R, Baboolal K. Influence of lifestyle modification in renal transplant recipients with postprandial hyperglycemia. *Transplantation* 2008;85:353-8.
44. Kuningas K, Driscoll J, Mair R, et al. Comparing Glycaemic Benefits of Active Versus Passive Lifestyle Intervention in Kidney Allograft Recipients: A Randomized Controlled Trial. *Transplantation* 2020;104:1491-9.
45. Kim Y, Jung AD, Dhar VK, et al. Laparoscopic sleeve gastrectomy improves renal transplant candidacy and posttransplant outcomes in morbidly obese patients. *Am J Transplant* 2018;18:410-6.
46. Kim Y, Bailey AJ, Morris MC, Kassam AF, Shah SA, Diwan TS. Kidney transplantation after sleeve gastrectomy in the morbidly obese candidate: results of a 2-year experience. *Surg Obes Relat Dis* 2020;16:10-4.
47. Hadjievangelou N, Kulendran M, McGlone ER, Reddy M, Khan OA. Is bariatric surgery in patients following renal transplantation safe and effective? A best evidence topic. *Int J Surg* 2016;28:191-5.
48. Diwan TS, Lee TC, Nagai S, et al. Obesity, transplantation, and bariatric surgery: An evolving solution for a growing epidemic. *Am J Transplant* 2020;20:2143-55.
49. Cohen E, Korah M, Callender G, Belfort de Aguiar R, Haakinson D. Metabolic Disorders with Kidney Transplant. *Clin J Am Soc Nephrol* 2020;15:732-42.
50. <https://www.easd.org/virtualmeeting/home.html#!resources/early-postoperative-basal-insulin-therapy-for-the-prevention-of-post-transplant-diabetes-onset-after-kidney-transplantation-itp-nodat-bb2c171d-d2ed-48aa-8942-600fe3ddf0a5>.
51. Utzschneider KM, Tong J, Montgomery B, et al. The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose. *Diabetes Care* 2008;31:108-13.
52. Haidinger M, Werzowa J, Hecking M, et al. Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation--a randomized, double-blind, placebo-controlled trial. *Am J Transplant* 2014;14:115-23.
53. Gaiffe E, Crepin T, Bamoulid J, et al. PRODIG (Prevention of new onset diabetes after transplantation by a short term treatment of Vildagliptin in the early renal post-transplant period) study: study protocol for a randomized controlled study. *Trials* 2019;20:375.
54. American Diabetes A. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020. *Diabetes Care* 2020;43:S98-S110.
55. Alnasrallah B, Goh TL, Chan LW, Manley P, Pilmore H. Transplantation and diabetes (Transdiab): a pilot randomised controlled trial of metformin in impaired glucose tolerance after kidney transplantation. *BMC Nephrol* 2019;20:147.
56. Chowdhury TA, Wahba M, Mallik R, et al. Association of British Clinical Diabetologists and Renal Association guidelines on the detection and management of diabetes post solid organ transplantation. *Diabet Med* 2021:e14523.
57. Turk T, Pietruck F, Dolff S, et al. Repaglinide in the management of new-onset diabetes mellitus after renal transplantation. *Am J Transplant* 2006;6:842-6.
58. Tuerk TR, Bandur S, Nuernberger J, et al. Gliquidone therapy of new-onset diabetes mellitus after kidney transplantation. *Clin Nephrol* 2008;70:26-32.
59. Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. *Nat Rev Endocrinol* 2012;8:728-42.

60. Pinelli NR, Patel A, Salinitri FD. Coadministration of liraglutide with tacrolimus in kidney transplant recipients: a case series. *Diabetes Care* 2013;36:e171-2.
61. Singh P, Pesavento TE, Washburn K, Walsh D, Meng S. Largest single-centre experience of dulaglutide for management of diabetes mellitus in solid organ transplant recipients. *Diabetes Obes Metab* 2019;21:1061-5.
62. Singh P, Taufeeq M, Pesavento TE, Washburn K, Walsh D, Meng S. Comparison of the glucagon-like-peptide-1 receptor agonists dulaglutide and liraglutide for the management of diabetes in solid organ transplant: A retrospective study. *Diabetes Obes Metab* 2020;22:879-84.
63. Sanyal D, Gupta S, Das P. A retrospective study evaluating efficacy and safety of linagliptin in treatment of NODAT (in renal transplant recipients) in a real world setting. *Indian J Endocrinol Metab* 2013;17:S203-5.
64. Strom Halden TA, Asberg A, Vik K, Hartmann A, Jenssen T. Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation. *Nephrol Dial Transplant* 2014;29:926-33.
65. Skotnicki AB, Szczudrawa R, Blicharski J. [Use of immunoglobulin preparations in hematology]. *Przegl Lek* 1987;44:292-302.
66. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *N Engl J Med* 2015;373:2117-28.
67. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. *N Engl J Med* 2017;377:644-57.
68. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med* 2019;380:347-57.
69. Heerspink HJL, Stefansson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. *N Engl J Med* 2020;383:1436-46.
70. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. *N Engl J Med* 2016;375:323-34.
71. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. *N Engl J Med* 2019;380:2295-306.
72. Perkovic V, de Zeeuw D, Mahaffey KW, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. *Lancet Diabetes Endocrinol* 2018;6:691-704.
73. Hecking M, Sharif A, Eller K, Jenssen T. Management of post-transplant diabetes: immunosuppression, early prevention, and novel antidiabetics. *Transpl Int* 2021;34:27-48.
74. Patel NH, J.; Farouk, S. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors & Kidney Transplantation: What Are We Waiting For? *Kidney360* 2021;10.34067/KID.0000732021; .
75. AlKindi F, Al-Omary HL, Hussain Q, Al Hakim M, Chaaban A, Boobes Y. Outcomes of SGLT2 Inhibitors Use in Diabetic Renal Transplant Patients. *Transplant Proc* 2020;52:175-8.
76. Rajasekeran H, Kim SJ, Cardella CJ, et al. Use of Canagliflozin in Kidney Transplant Recipients for the Treatment of Type 2 Diabetes: A Case Series. *Diabetes Care* 2017;40:e75-e6.
77. Mahling M, Schork A, Nadalin S, Fritsche A, Heyne N, Guthoff M. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibition in Kidney Transplant Recipients with Diabetes Mellitus. *Kidney Blood Press Res* 2019;44:984-92.
78. Shah M, Virani Z, Rajput P, Shah B. Efficacy and Safety of Canagliflozin in Kidney Transplant Patients. *Indian J Nephrol* 2019;29:278-81.
79. Halden TAS, Kvitne KE, Midtvedt K, et al. Efficacy and Safety of Empagliflozin in Renal Transplant Recipients With Posttransplant Diabetes Mellitus. *Diabetes Care* 2019;42:1067-74.
80. Schwaiger E, Burghart L, Signorini L, et al. Empagliflozin in posttransplantation diabetes mellitus: A prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety. *Am J Transplant* 2019;19:907-19.

81. Song CC, Brown A, Winstead R, et al. Early initiation of sodium-glucose linked transporter inhibitors (SGLT-2i) and associated metabolic and electrolyte outcomes in diabetic kidney transplant recipients. *Endocrinol Diabetes Metab* 2021;4:e00185.
82. Attallah N, Yassine L. Use of Empagliflozin in Recipients of Kidney Transplant: A Report of 8 Cases. *Transplant Proc* 2019;51:3275-80.
83. Wissing KM, Abramowicz D, Weekers L, et al. Prospective randomized study of conversion from tacrolimus to cyclosporine A to improve glucose metabolism in patients with posttransplant diabetes mellitus after renal transplantation. *Am J Transplant* 2018;18:1726-34.
84. Boots JM, van Duijnhoven EM, Christiaans MH, Wolffenbuttel BH, van Hooff JP. Glucose metabolism in renal transplant recipients on tacrolimus: the effect of steroid withdrawal and tacrolimus trough level reduction. *J Am Soc Nephrol* 2002;13:221-7.
85. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. *N Engl J Med* 2007;357:2562-75.
86. Muller MM, Schwaiger E, Kurnikowski A, et al. Glucose Metabolism After Kidney Transplantation: Insulin Release and Sensitivity With Tacrolimus- Versus Belatacept-Based Immunosuppression. *Am J Kidney Dis* 2021;77:462-4.
87. Pascual J, Galeano C, Royuela A, Zamora J. A systematic review on steroid withdrawal between 3 and 6 months after kidney transplantation. *Transplantation* 2010;90:343-9.
88. Pascual J, Royuela A, Galeano C, Crespo M, Zamora J. Very early steroid withdrawal or complete avoidance for kidney transplant recipients: a systematic review. *Nephrol Dial Transplant* 2012;27:825-32.
89. Woodle ES, First MR, Pirsch J, et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. *Ann Surg* 2008;248:564-77.
90. Haller MCR, A.; Nagler, E.V.; Pascual, J.; Webster, A.C. . Steroid avoidance or withdrawal for kidney transplant recipients. *Cochrane Database of Systematic Reviews* 2016.
91. Thomusch O, Wiesener M, Opgenoorth M, et al. Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial. *Lancet* 2016;388:3006-16.
92. Midtvedt K, Hjelmestaeth J, Hartmann A, et al. Insulin resistance after renal transplantation: the effect of steroid dose reduction and withdrawal. *J Am Soc Nephrol* 2004;15:3233-9.
93. American Diabetes A. Standards of Medical Care in Diabetes-2018 Abridged for Primary Care Providers. *Clin Diabetes* 2018;36:14-37.
94. Foster NC, Beck RW, Miller KM, et al. State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018. *Diabetes Technol Ther* 2019;21:66-72.
95. Bosi E, Choudhary P, de Valk HW, et al. Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemia-prone adults with type 1 diabetes (SMILE): an open-label randomised controlled trial. *Lancet Diabetes Endocrinol* 2019;7:462-72.
96. Laffel LM, Kanapka LG, Beck RW, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Adolescents and Young Adults With Type 1 Diabetes: A Randomized Clinical Trial. *JAMA* 2020;323:2388-96.
97. Redfield RR, Rickels MR, Naji A, Odorico JS. Pancreas Transplantation in the Modern Era. *Gastroenterol Clin North Am* 2016;45:145-66.
98. Pham PH, Stalter LN, Martinez EJ, et al. Large single center results of simultaneous pancreas-kidney transplantation in patients with type 2 diabetes. *Am J Transplant* 2020.
99. Markmann JF, Rickels MR, Eggerman TL, et al. Phase 3 trial of human islet-after-kidney transplantation in type 1 diabetes. *Am J Transplant* 2021;21:1477-92.
100. Fridell JA, Stratta RJ. Islet or pancreas after kidney transplantation: Is the whole still greater than some of its parts? *Am J Transplant* 2021;21:1363-4.

101. Cosio FG, Pesavento TE, Osei K, Henry ML, Ferguson RM. Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years. *Kidney Int* 2001;59:732-7.
102. Cron DC, Noon KA, Cote DR, et al. Using analytic morphomics to describe body composition associated with post-kidney transplantation diabetes mellitus. *Clin Transplant* 2017;31.
103. von Düring ME, Jenssen T, Bollerslev J, et al. Visceral fat is better related to impaired glucose metabolism than body mass index after kidney transplantation. *Transpl Int* 2015;28:1162-71.
104. McCaughan JA, McKnight AJ, Maxwell AP. Genetics of new-onset diabetes after transplantation. *J Am Soc Nephrol* 2014;25:1037-49.
105. Chen T, Jia H, Li J, Chen X, Zhou H, Tian H. New onset diabetes mellitus after liver transplantation and hepatitis C virus infection: meta-analysis of clinical studies. *Transpl Int* 2009;22:408-15.
106. Baid S, Cosimi AB, Farrell ML, et al. Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. *Transplantation* 2001;72:1066-72.
107. Huang JW, Famure O, Li Y, Kim SJ. Hypomagnesemia and the Risk of New-Onset Diabetes Mellitus after Kidney Transplantation. *J Am Soc Nephrol* 2016;27:1793-800.
108. Hjeltnes J, Flyvbjerg A, Jenssen T, et al. Hypoadiponectinemia is associated with insulin resistance and glucose intolerance after renal transplantation: impact of immunosuppressive and antihypertensive drug therapy. *Clin J Am Soc Nephrol* 2006;1:575-82.